A complementary downstream mechanism involves immunomodulatory effects, consisting of inhibition of proinflammatory cytokine release, such as TNF-α and IL-6, via 5-HT2A agonism, potentially attenuating the inflammatory component of MDD. The gene discussed is IL6; the disease is major depressive disorder.